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Abstract. The association of chronic myeloid leukemia (CML) 
with other myeloproliferative neoplasms (MPNs), in particular 
with the V617F mutation in the Janus kinase 2 (JAK2) gene, is 
very uncommon, and there are only a few cases reported in the 
literature. In the present study, the case of a 73-year-old man 
with CML and persistent thrombocytosis, is reported. The 
patient achieved a complete cytogenetic response and major 
molecular response (MR) with imatinib. The patient presented 
JAK2 V617F mutation, and bone marrow morphology was 
consistent with essential thrombocythemia. The patient was 
treated with imatinib and hydroxyurea to control the platelet 
count, and maintains complete MR with imatinib upon 
10 years of follow-up. Although rare, the association of break-
point cluster region-Abelson rearrangement and JAK2 V617F 
mutation should be investigated in patients with MPN, since 
both genetic anomalies may be present at diagnosis or may 
emerge during treatment, and require different therapeutic 
approaches.
Introduction
Myeloproliferative neoplasms (MPNs) correspond to a clonal 
proliferation of hematopoietic cells, resulting in expansion of 
≥1 lineages (1). Molecular markers aid to characterize these 
disorders, and are useful for diagnosis and follow-up of MPNs, 
since they enable the detection of minimal residual disease, 
such as breakpoint cluster region-Abelson (BCR-ABL) rear-
rangement in chronic myeloid leukemia (CML) (1). The Janus 
kinase 2 (JAK2) V617F mutation is present in 95% of patients 
with polycythemia vera (PV) and in ~50% of patients with 
essential thrombocythemia (ET) and idiopathic myelofibrosis 
(MF) (2-5). The association of CML with other forms of 
MPN, in particular with the JAK2 V617F mutation, is very 
uncommon, and there are limited cases reported in the litera-
ture (6-8). Pieri et al (9) performed a screening of 314 patients 
with CML and identified 8 cases (2.55%) with concomitant 
JAK2 V617F mutation.
Despite the rarity of the concomitant detection of 
BCR-ABL and JAK2 V617F mutation, it is of great impor-
tance to recognize and investigate this association, particularly 
when the disease has an unusual course and the diagnosis of 
other MPNs may have practical therapeutic consequences. 
Therefore, in the present study, the case of a patient diagnosed 
with CML, in whom an ET with JAK2 V617F mutation was 
detected during the course of CML follow-up, is reported.
Case report
In March 2003, a 73-year-old male patient was referred to the 
Hematology and Hemotherapy Center of the University of 
Campinas (Campinas, Brazil) for a hematological evaluation, 
due to leukocytosis detected in a routine exam. The patient 
had no clinical symptoms, and presented a white blood cell 
count of 49.4x109 cells/l [normal range, 5.2-12.4x109 cells/l; 
2% eosinophils (normal range, 0-7%), 4.0% basophils 
(normal range, 0-1.5%), 1% blasts (normal range, 0%) and 
2% promyelocytes (normal range, 0%)], a platelets count 
of 607.0x109 platelets/l (normal range, 150-450x109/l) and 
hemoglobin levels of 12.2 g/dl (normal range, 13.5-17.5 g/dl). 
Diagnosis of CML was confirmed by conventional cytoge-
netic analysis, using the Giemsa-trypsin-Wright stain banding 
technique, which revealed the presence of the translocation 
t(9;22)(q34;q11) in 20/20 metaphases examined, and by 
reverse transcription-polymerase chain reaction (RT-PCR), 
which detected the BCR-ABL rearrangement (b3a2) (10).
In consequence, the patient was treated with interferon 
alfa-2a (6 million units/day; subcutaneous; Roche Diagnostics, 
Basel, Switzerland) between April and May 2003, with no hema-
tological response. Thus, treatment with imatinib (400 mg/day; 
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oral; Glivec; Novartis, Basel, Switzerland) was initiated in 
May 2003. Subsequently, the white blood cell count returned 
to the normal range, but the platelet count remained elevated. 
The patient did not achieve a normal platelet count, despite 
increasing the dose of imatinib to 700 mg/day, but achieved 
complete cytogenetic remission 6 months later. However, his 
platelet count increased progressively. Therefore other causes 
of thrombocytosis were investigated. Ferritin levels were 
normal and the patient showed increased prostate‑specific 
antigen (PSA) levels (6.7 ng/ml; normal range, 0-4 ng/ml), 
which suggested prostate cancer. Prostate cancer was diag-
nosed by prostate biopsy. The patient was treated with local 
radiotherapy with complete remission. Despite the normaliza-
tion observed in the PSA levels, the thrombocytosis persisted. 
In November 2006, the patient achieved a major molecular 
response (MR) in BCR-ABL levels, but platelets counts 
remained increased (622x109 platelets/l). To further investi-
gate whether other MPNs were involved, the JAK2 V617F 
mutation was investigated and detected by restriction 
fragment length polymorphism analysis, as described previ-
ously (3), and confirmed by direct Sanger sequencing. The 
bone marrow biopsies conducted at the time of diagnosis 
and following treatment for CML were reanalyzed, (Figs. 1 
and 2, respectively). The post-treatment biopsy displayed 
global hypercellularity, increased myeloid:erythroid ratio 
and hyperplasia of atypical megakaryocytes, with no fibrosis. 
The morphology of the megakaryocytes was consistent with 
ET.
The imatinib dose was then decreased to 400 mg/day, as 
the thrombocytosis was associated with ET and not due to 
resistant CML. Since then, hydroxyurea (500 mg/day; oral; 
Hydrea; Bristol Myers-Squibb, New York City, NY, USA), 
has been administered concomitantly to control thrombo-
cytosis. In the last follow-up, in December 2015, >10 years 
following the start of imatinib treatment, the patient main-
tains a complete cytogenetic response and a deep molecular 
response [MR 4.5, according to the international scale (11)], 
in the BCR-ABL transcripts levels detected by RT-PCR, 
using a previously described technique (12). No thrombotic or 
hemorrhagic events has occurred.
Discussion
The association of JAK2 mutations and BCR-ABL rearrange-
ment is infrequent, and was recently reported in association 
with MF (6,7,13,14) and PV (8,15,16). In a previous report by 
the present authors, the presence of the JAK2 V617F mutation 
in CML was reported to be rare, with the present case being 
the only one detected among 55 cases of CML analyzed (17).
Bee et al (8) reported a case of PV with JAK2 V617F 
mutation and BCR-ABL rearrangement at diagnosis. In that 
report, the patient presented a decrease in V617F alleles when 
the burden of BCR-ABL messenger RNA increased, and 
reappearance of V617F clones following the administration of 
imatinib. A similar case was reported by Ursuleac et al (16), 
where a patient with PV developed CML following 7 years of 
PV diagnosis. Wahlin et al (18) described a case of ET with 
emergence of CML during treatment with hydroxyurea. A 
recent study by Mizutani et al (19) reported the emergence of 
CML during treatment for ET in a patient following 9 years 
of diagnosis. By contrast, Véronèse et al (6) reported a case 
of CML developing ET upon achieving BCR-ABL major 
MR, similarly to the present findings. In that case, the JAK2 
clone was present at low levels at CML diagnosis, while in the 
present patient, the bone marrow histology was consistent with 
ET when the mutation was detected, although molecular data 
regarding the JAK2 mutation was not available at the time of 
diagnosis.
In conclusion, the present report emphasizes that the pres-
ence of persistent or increasing thrombocytosis in CML, which 
is not responsive to treatment, should always be further inves-
tigated. Bone marrow histology may be useful to exclude other 
malignant diseases or to confirm other MPNs. In the present 
case, JAK2 V617F mutation analysis was determinant in the 
Figure 1. Bone marrow histology at diagnosis revealed chronic myeloid 
leukemia, according to the hypercellular bone marrow with predomi-
nance of the myeloid series and atypical megakaryocytes observed by 
hematoxylin and eosin staining (Merck Millipore, Darmstadt, Germany). 
Magnification, x1,000 (Olympus CX31 optical microscope; Olympus 
America, Inc., Center Valley, PA, USA).
Figure 2. Bone marrow histology following treatment of chronic myeloid leu-
kemia revealed features of essential thrombocythemia, such as proliferation 
of pleomorphic, hyperlobated megakaryocytes. Erythroblasts and myeloid 
elements with normal morphology were also present. Hematoxylin and 
eosin staining (Merck Millipore, Darmstadt, Germany); magnification, x400 
(Olympus CX31 optical microscope; Olympus America, Inc., Center Valley, 
PA, USA). A mild increase in reticulin fibers (Easypath‑Erviegas, São Paulo, 
Brazil) was observed (inset; silver impregnation; magnification, x400) 
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final characterization of ET associated with CML. Molecular 
characterization of MPN at the time of diagnosis is necessary 
to establish a correct diagnosis and to detect concomitant 
clones. Although rare, the association of ET with CML may 
be identified at diagnosis or may appear during treatment, and 
may require to alter the therapeutic approach.
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